関連する実験動画
Updated: Sep 10, 2025

11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
38.3K
中脳ドーパミンニューロンの慢性的な過活性化により,優先ドーパミンニューロン変性が生じます
Katerina Rademacher1,2,3, Zak Doric1,2, Dominik Haddad1
1Gladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.
eLife
|August 26, 2025
まとめ
ドーパミンニューロンの活性が増加すると,パーキンソン病 (PD) の進行が加速する. この研究では マウスモデルを用いて 過剰活動性のドーパミンニューロンが 神経変性を引き起こすことを示し PDのメカニズムについて 新たな洞察を提供しました
科学分野:
- 神経科学
- 神経変性疾患
- 分子生物学
背景:
- パーキンソン病 (PD) はドーパミンニューロンの喪失を伴うが,変性の正確な原因は不明である.
- ドーパミンの神経細胞活動の変化はPDで疑われるが,神経変異を誘発するその役割は十分に理解されていない.
研究 の 目的:
- マウスモデルでの神経変性に対する慢性的に増加したドーパミンニューロンの影響を調査する.
- ニューロンの死とPDの病理に繋がる 根本的なメカニズムを探る
主な方法:
- ドーパミンニューロンの持続的な過剰活性化を誘導する化学遺伝 (DREADD) マウスモデルを開発した.
- ニューロンの過剰活性が確認された
- 行動の変化,神経変性パターン,カルシウムレベル, 空間転写学による遺伝子発現を分析した.
主要な成果:
- ドーパミンニューロンの慢性的な過活性化により,運動運動の変化と昼夜リズム障害が発生した.
- PDの選択的脆弱性を反映した substantia nigra pars compacta (SNc) 投影の好ましい退化が観察されました.
- 基礎値のカルシウム濃度の持続的な上昇を特定し,多動性による毒性に関する分子洞察を提供しました.
結論:
- Substantia nigra pars compacta ドーパミンのニューロンは神経活動の増加に特異的な脆弱性を表しています.
- ドーパミンニューロンの持続的な過活動性は,神経変性を誘発し,パーキンソン病の病原性におけるその役割を支持する.
関連する概念動画
Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703
Parkinson's Disease: Treatment
377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
947
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
947
Excitatory and Inhibitory Effects of Neurotransmitters
10.8K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.8K

